Anti-CD105 [huRH105-1]

Catalogue Number: AB04017-10.0-BT-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Alias:	endoglin; ENG
Shipping Condition:	Blue Ice
Unit(s):	1 mg
Host name:	Human
Clone:	huRH105-1
Isotype:	IgG1
Immunogen:	The original mouse parental antibody RH105-1 was generated by intraperitoneal immunization of BALB/c VAF mice with rat CD105-expressing 300-19 cells. This antibody was synthetically engineered to mimic a binding specificity of the original RH105-1, by grafting the CDRs of the parental antibody onto human framework segments.
Application:	FC, InVitroA, InVivoA

Overview
Datasheets

Additional Text

Gene Name

ENG

Gene ID

2022

Uniprot ID

P17813

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.

Application Notes

This antibody was used for detection of CD105 expressed on Vero cell lines by flow cytometry (Kd = 0.024 nM). The ability of the antibody to induce apoptosis on HUVEC cells was measured. Results showed that treatment with the antibody induced apoptosis of up to 47% of HUVEC cells at a concentration of 0.25 µg/mL. Further, the antibody induced a greater percentage of cells to undergo apoptosis under hypoxic conditions. The binding affinity of the antibody and the antibody conjugated to SPDB-DM4 was assayed by flow cytometry. The value of the apparent dissociation constants were calculated Kd = 1.63 nM and 2.12 nM, respectively. Treatment of HUVEC cells with huRH105-l-SMCC-DMl completely reduced viability of HUVEC cells with an EC50 of 0.12 nM in in vitro cytotoxicity experiments, while treatment of HUVEC cells with huRH105-l-SPDB-DM4 completely reduced viability with an EC50 of 0.21 nM. The antibody bound to Rat Aortic Endothelial Cells (RAOEC) by flow cytometry analysis (Kd = 0.13 nM). The ability the conjugate antibodies to inhibit cell growth of RAOEC cells was measured using an in vitro cytotoxicity assay. Treatment with huRH105-l- SMCC-DM1 completely reduced viability of RAOEC cells with an EC50of 0.48 nM for huRH105-l-SMCC-DMl and 1.1 nM for huRH105-l-SPDB-DM4. Analysis of in vivo efficacy of huRH105-l-SMCC-DMl in combination with bevacizumab in A2780 and HCT116 rat xenograft models showed improved efficacy compared to the control experiment. Analysis of in vivo efficacy of huRH105-l-SMCC-DMl alone in an U87MG rat xenograft model showed improved efficacy compared to the control experiment (WO2012149412A2).

Short Description

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

AB04017-10.0-BT Datasheet

Price

£1,825.00

-

Quantity
Unit Size

Find out about delivery